Page last updated: 2024-10-21

2-amino-5-phosphonovalerate and Movement Disorders

2-amino-5-phosphonovalerate has been researched along with Movement Disorders in 1 studies

2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.

Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Turski, L1
Klockgether, T1
Turski, WA1
Schwarz, M1
Sontag, KH1

Other Studies

1 other study available for 2-amino-5-phosphonovalerate and Movement Disorders

ArticleYear
Blockade of excitatory neurotransmission in the globus pallidus induces rigidity and akinesia in the rat: implications for excitatory neurotransmission in pathogenesis of Parkinson's diseases.
    Brain research, 1990, Mar-26, Volume: 512, Issue:1

    Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Corpus Striatum; Dose-Response Relationship, Drug

1990